Advertisement

AIDS and Behavior

, Volume 22, Issue 7, pp 2334–2339 | Cite as

Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia

  • Michael J. Vinikoor
  • Zude Zyambo
  • Monde Muyoyeta
  • Geetanjali Chander
  • Michael S. Saag
  • Karen Cropsey
Original Paper

Abstract

In an HIV-hepatitis B virus (HIV-HBV) coinfection cohort in Zambia, we piloted a qualitative point-of-care (POC) test for urine Ethyl glucuronide (uEtG), assessed concordance between uEtG and alcohol use disorders identification test-consumption (AUDIT-C), and identified epidemiological factors associated with underreporting (defined as uEtG-positivity with last reported drink > 7 days prior). Among 211 participants (40.8% women), there were 44 (20.8%) lifetime abstainers, 32 (15.2%) former drinkers, and 135 (64.0%) current drinkers, including 106 (50.2%) with unhealthy drinking per AUDIT-C. Eighty-seven (41.2%) were uEtG-positive including 64 of 65 (98.5%) who drank ≤ 3 days prior and 17 of 134 (12.7%) underreported, all of whom admitted to recent drinking when results were discussed. uEtG was moderately concordant with AUDIT-C. Past drinking (versus lifetime abstinence) and longer time on antiretrovirals (≥ 12 months) were associated with underreporting. These data support further use of POC alcohol biomarkers in HIV and hepatitis research and clinical settings.

Keywords

Alcohol use disorder HIV/AIDS Africa Hepatitis B virus Ethyl glucuronide Alcohol biomarker 

Notes

Acknowledgements

We acknowledge the CIDRZ Hep Team for their dedication to the HIV-HBV coinfection cohort and their specific role in Ethyl glucuronide testing and alcohol reduction counseling for this study. This study was funded by the Fogarty International Center (K01TW009998) and the National Institute of Allergy and Infectious Diseases (U01AI120796) at the U.S. National Institutes of Health.

References

  1. 1.
    Hahn JA, Woolf-King SE, Muyindike W. Adding fuel to the fire: alcohol’s effect on the HIV epidemic in Sub-Saharan Africa. Current HIV/AIDS Reports. 2011;8(3):172–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci. 2007;8(2):141.CrossRefPubMedGoogle Scholar
  3. 3.
    Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jaquet A, Ekouevi DK, Bashi J, Aboubakrine M, Messou E, Maiga M, et al. Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction. 2010;105(8):1416–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav. 2017;21(7):1825–35.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Canan C, Lau B, McCaul M, Keruly J, Moore R, Chander G. Effect of alcohol consumption on all-cause and liver-related mortality among HIV-infected individuals. HIV Med. 2017;18:332–41.CrossRefPubMedGoogle Scholar
  7. 7.
    Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, et al. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend. 2016;161:95–103.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.CrossRefPubMedGoogle Scholar
  9. 9.
    Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst. 2004;96(24):1851–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Asiimwe SB, Fatch R, Emenyonu NI, Muyindike WR, Kekibiina A, Santos GM, et al. Comparison of traditional and novel self-report measures to an alcohol biomarker for quantifying alcohol consumption among HIV-infected adults in sub-Saharan Africa. Alcoholism. 2015;39(8):1518–27.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction. 2003;98(s2):1–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Sundararajan R, Wyatt MA, Woolf-King S, Pisarski EE, Emenyonu N, Muyindike WR, et al. Qualitative study of changes in alcohol use among HIV-infected adults entering care and treatment for HIV/AIDS in rural southwest Uganda. AIDS Behav. 2015;19(4):732–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Anton RF. Commentary on: ethylglucuronide and ethyl sulfate assays in clinical trials, interpretation 1 and limitations: results of a dose ranging alcohol challenge study and two clinical trials. Alcohol Clin Exp Res. 2014;38(7):1826.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jatlow PI, Agro A, Wu R, Nadim H, Toll BA, Ralevski E, et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcoholism. 2014;38(7):2056–65.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Leickly E, McDonell MG, Vilardaga R, Angelo FA, Lowe JM, McPherson S, et al. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse. 2015;41(3):246–50.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hahn JA, Emenyonu NI, Fatch R, Muyindike WR, Kekiibina A, Carrico AW, et al. Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self-report. Addiction. 2016;111(2):272–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Papas RK, Gakinya BN, Mwaniki MM, Keter AK, Lee H, Loxley MP, et al. Associations between the phosphatidylethanol alcohol biomarker and self-reported alcohol use in a sample of HIV-infected outpatient drinkers in western Kenya. Alcoholism. 2016;40(8):1779–87.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wandeler G, Musukuma K, Zuercher S, Vinikoor MJ, Llenas J, Musa A, et al. Hepatitis B infection, viral load and resistance in HIV-infected patients in Mozambique and Zambia. PLoS ONE. 2016;11:e0152043.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zambian Ministry of Health. Zambia consolidated guidelines for the treatment and prevention of HIV infection. Zambia: Lusaka; 2014.Google Scholar
  20. 20.
    Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcoholism. 2007;31(7):1208–17.CrossRefPubMedGoogle Scholar
  21. 21.
    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Arndt T, Grüner J, Schröfel S, Stemmerich K. False-positive ethyl glucuronide immunoassay screening caused by a propyl alcohol-based hand sanitizer. Forensic Sci Int. 2012;223(1):359–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Chishinga N, Kinyanda E, Weiss HA, Patel V, Ayles H, Seedat S. Validation of brief screening tools for depressive and alcohol use disorders among TB and HIV patients in primary care in Zambia. BMC Psychiatry. 2011;11(1):1.CrossRefGoogle Scholar
  24. 24.
    Parry CD, Kekwaletswe C, Shuper PA, Nkosi S, Myers BJ, Morojele NK. Heavy alcohol use in patients on highly active antiretroviral therapy: what responses are needed? SAMJ. 2016;106(6):567–8.CrossRefGoogle Scholar
  25. 25.
    Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Crane HM, Nance RM, Merrill JO, Hutton H, Chander G, McCaul ME, et al. Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders. AIDS Care. 2017;29(2):177–84.CrossRefPubMedGoogle Scholar
  27. 27.
    McDonell MG, Graves MC, West II, Ries RK, Donovan DM, Bumgardner K, et al. Utility of point-of-care urine drug tests in the treatment of primary care patients with drug use disorders. J Addict Med. 2016;10(3):196–201.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, et al. A randomized controlled trial of ethyl glucuronide-based contingency management for outpatients with co-occurring alcohol use disorders and serious mental illness. Am J Psychiatry. 2017;174(4):370–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Michael J. Vinikoor
    • 1
    • 2
    • 3
  • Zude Zyambo
    • 1
  • Monde Muyoyeta
    • 1
    • 3
  • Geetanjali Chander
    • 4
  • Michael S. Saag
    • 2
  • Karen Cropsey
    • 5
  1. 1.Centre for Infectious Disease Research in ZambiaLusakaZambia
  2. 2.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.School of MedicineUniversity of ZambiaLusakaZambia
  4. 4.Department of MedicineJohns Hopkins UniversityBaltimoreUSA
  5. 5.Department of PsychiatryUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations